Forte Biosciences Inc.

NASDAQ: FBRX · Real-Time Price · USD
11.85
1.03 (9.52%)
At close: Aug 15, 2025, 3:59 PM
11.61
-2.03%
After-hours: Aug 15, 2025, 04:53 PM EDT

Forte Biosciences Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 6K 6K 6K 6K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
10K 19K 25K 28K 18K 9K 3K n/a n/a n/a n/a 9K 22K 36K 36K 27K 14K
Gross Profit
-10K -19K -19K -22K -12K -3K -3K n/a n/a n/a n/a -9K -22K -36K -36K -27K -14K
Operating Income
-44.92M -36.6M -35.63M -37.22M -33.44M -32.49M -31.04M -24.25M -18.24M -13.9M -12.26M -16.53M -19.26M -21.49M -22.68M -19.99M -49M
Interest Income
n/a n/a 1.12M 1.12M 1.12M 1.12M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-43.71M -35.48M -34.2M -35.76M -32.14M -31.48M -30.48M -23.93M -18.07M -13.88M -12.34M -16.69M -19.47M -21.71M -22.94M -20.29M -49.24M
Net Income
-43.71M -35.48M -34.2M -35.76M -32.14M -31.37M -30.39M -23.81M -17.96M -13.93M -12.39M -16.76M -19.52M -21.71M -22.94M -20.29M -49.24M
Selling & General & Admin
15.39M 15.4M 16.09M 17.18M 11.99M 10.62M 10.26M 8.46M 8.55M 8.3M 7.8M 7.8M 8.04M 7.63M 7.15M 6.43M 4.97M
Research & Development
29.23M 21.04M 19.38M 20.03M 21.43M 21.86M 20.78M 15.79M 9.69M 5.59M 4.46M 8.73M 11.22M 13.85M 15.53M 13.56M 11.97M
Other Expenses
300K 150K 150K n/a n/a n/a n/a 23K 8K 8K 8K -67K -52K -52K -52K n/a -7K
Operating Expenses
44.91M 36.58M 35.62M 37.2M 33.42M 32.48M 31.04M 24.25M 18.24M 13.9M 12.26M 16.53M 19.26M 21.49M 22.68M 19.99M 16.94M
Interest Expense
n/a n/a 102K 102K 102K 102K 6K 6K 21K 74K 110K 110K 95K 42K n/a n/a n/a
Selling & Marketing Expenses
n/a -9K -15K -15K -15K -6K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
28.8M 36.6M 35.63M 37.22M 33.44M 32.49M 31.04M 24.25M 18.24M 13.9M 12.26M 16.53M 19.26M 21.49M 22.68M 19.99M 16.94M
Income Tax Expense
34.28K n/a -34.28K -37.28K -46.31K -114.03K -108.03K -128.03K -104K 51K 45K 68K 53K n/a n/a n/a n/a
Shares Outstanding (Basic)
11.4M 6.39M 1.85M 1.85M 1.55M 1.45M 1.51M 841.87K 840.27K 840K 757.1K 590.45K 590.39K 590.18K 569.65K 544.13K 530.12K
Shares Outstanding (Diluted)
11.4M 6.39M 1.85M 1.85M 1.55M 1.45M 1.51M 841.87K 840.27K 840K 757.1K 590.45K 590.39K 590.18K 569.65K 544.13K 530.12K
EPS (Basic)
-15.69 -19.09 -20.13 -22.16 -25.95 -29.22 -30.98 -28.9 -23.47 -19.78 -19.64 -28.76 -34.3 -39.01 -42.27 -51.82 -279.2
EPS (Diluted)
-15.69 -19.09 -20.13 -22.16 -25.95 -29.22 -30.98 -28.9 -23.47 -19.78 -19.64 -28.76 -34.3 -39.01 -42.27 -51.82 -279.2
EBITDA
-44.89M -36.56M -35.6M -37.19M -33.42M -32.48M -31.04M -24.25M -18.24M -13.9M -12.26M -16.52M -19.24M -21.45M -22.63M -19.93M -16.88M
EBIT
-28.8M -36.6M -35.63M -37.22M -33.44M -32.49M -31.04M -24.25M -18.24M -13.9M -12.26M -16.53M -19.26M -21.49M -22.68M -19.99M -16.94M
Depreciation & Amortization
30K 39K 35K 28K 9.05M 15.9M 15.9M 15.91M 6.88M 36K -15K -15K -11K -6K 50K 54K 55K